Logotype for Tharimmune Inc

Tharimmune (THAR) investor relations material

Tharimmune Q2 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Tharimmune Inc
Q2 2025 earnings summary14 Aug, 2025

Executive summary

  • Clinical-stage biotech focused on immunology and inflammation, advancing TH104 for opioid overdose prophylaxis and pruritus in PBC, and developing early-stage immuno-oncology assets including bispecific antibodies and novel delivery platforms.

  • Positive FDA feedback received for TH104's new indication, enabling a 505(b)(2) NDA pathway with no additional clinical trials required for the lead program.

  • Multiple licensing agreements in place, including with Avior, Intract, and ABSI, supporting pipeline expansion and technology access.

  • Strategic focus on capital efficiency, partnerships, and potential M&A to maximize pipeline value.

Financial highlights

  • Net loss for Q2 2025 was $1.86 million, compared to $2.33 million in Q2 2024; net loss for the six months ended June 30, 2025 was $4.40 million, down from $4.58 million year-over-year.

  • Research and development expenses decreased 45% year-over-year to $0.55 million for Q2 2025, primarily due to lower pre-clinical and license fees, offset by higher stock-based compensation.

  • General and administrative expenses decreased 5% to $1.30 million for Q2 2025, with lower personnel costs partially offset by higher investor relations fees.

  • Cash and cash equivalents were $2.24 million as of June 30, 2025, down from $3.56 million at year-end 2024.

  • Accumulated deficit reached $41.3 million as of June 30, 2025.

Outlook and guidance

  • Substantial additional funding is required to support future operations; management has concluded that substantial doubt exists about the ability to continue as a going concern for at least one year.

  • Plans to seek additional capital through equity or debt offerings, partnerships, or grants, but no assurance of success or timing.

  • Focus remains on advancing TH104 regulatory filings and progressing CMC activities for NDA submission.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Tharimmune earnings date

Logotype for Tharimmune Inc
Q3 20256 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Tharimmune earnings date

Logotype for Tharimmune Inc
Q3 20256 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Tharimmune Inc. is a biopharmaceutical company focused on the development of immune-modulating therapies for inflammatory diseases and cancer. The company specializes in small molecule and biologic drug candidates designed to regulate immune responses and target disease pathways. Tharimmune conducts clinical research and drug development to address unmet medical needs in autoimmune disorders, oncology, and fibrosis-related conditions. The company is headquartered in Westlake Village, California, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage